Furmonertinib
Furmonertinib is a Chinese lung cancer pill of the same class as osimertinib, which more than doubled the time before cancer grew compared with gefitinib in the FURLONG trial.
Overview
Developed by Shanghai Allist Pharmaceuticals; approved by the NMPA in March 2021 for EGFR T790M-positive NSCLC after earlier EGFR inhibitors and in June 2022 for first-line EGFR-mutant NSCLC on FURLONG (358 patients: median progression-free survival 20.8 versus 11.1 months with gefitinib, hazard ratio 0.44). A higher dose is being developed for EGFR exon 20 insertions, where ArriVent BioPharma holds ex-China rights and is running the global FURVENT phase 3 trial. Adjuvant and central nervous system studies continue.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas: how tumours escape and what closes the route · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| China | 2021 | EGFR T790M-positive locally advanced or metastatic NSCLC after EGFR TKI therapy |
| China | 2022 | First-line EGFR exon 19 deletion or L858R NSCLC (FURLONG) |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"Furmonertinib" OR ABSTRACT:"Furmonertinib" OR TITLE:"Ivesa" OR ABSTRACT:"Ivesa" OR TITLE:"AST2818" OR ABSTRACT:"AST2818" OR TITLE:"alflutinib" OR ABSTRACT:"alflutinib") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Furmonertinib, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductAumolertinib
Shares EGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M), RAS / RAF / MEK / ERK (MAPK), EGFR, Small-molecule kinase inhibitors and the tag china.
- ProductIcotinib
Shares RAS / RAF / MEK / ERK (MAPK), EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
- TrialAENEAS
Shares FURLONG, EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
- ProductSavolitinib
Shares RAS / RAF / MEK / ERK (MAPK), EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
- ProductGarsorasib
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
- ProductFulzerasib
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
- TrialALTER 0303
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
- ProductDonafenib
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors and the tag china.